Title |
Everolimus Plus Exemestane in Postmenopausal Patients with HR+ Breast Cancer: BOLERO-2 Final Progression-Free Survival Analysis
|
---|---|
Published in |
Advances in Therapy, October 2013
|
DOI | 10.1007/s12325-013-0060-1 |
Pubmed ID | |
Authors |
Denise A. Yardley, Shinzaburo Noguchi, Kathleen I. Pritchard, Howard A. Burris, José Baselga, Michael Gnant, Gabriel N. Hortobagyi, Mario Campone, Barbara Pistilli, Martine Piccart, Bohuslav Melichar, Katarina Petrakova, Francis P. Arena, Frans Erdkamp, Wael A. Harb, Wentao Feng, Ayelet Cahana, Tetiana Taran, David Lebwohl, Hope S. Rugo |
Abstract |
Effective treatments for hormone-receptor-positive (HR(+)) breast cancer (BC) following relapse/progression on nonsteroidal aromatase inhibitor (NSAI) therapy are needed. Initial Breast Cancer Trials of OraL EveROlimus-2 (BOLERO-2) trial data demonstrated that everolimus and exemestane significantly prolonged progression-free survival (PFS) versus placebo plus exemestane alone in this patient population. |
X Demographics
Geographical breakdown
Country | Count | As % |
---|---|---|
Italy | 1 | 100% |
Demographic breakdown
Type | Count | As % |
---|---|---|
Practitioners (doctors, other healthcare professionals) | 1 | 100% |
Mendeley readers
Geographical breakdown
Country | Count | As % |
---|---|---|
United States | 3 | <1% |
Ecuador | 2 | <1% |
Chile | 1 | <1% |
Portugal | 1 | <1% |
Canada | 1 | <1% |
Brazil | 1 | <1% |
Japan | 1 | <1% |
China | 1 | <1% |
Unknown | 325 | 97% |
Demographic breakdown
Readers by professional status | Count | As % |
---|---|---|
Researcher | 44 | 13% |
Other | 43 | 13% |
Student > Ph. D. Student | 37 | 11% |
Student > Master | 37 | 11% |
Student > Bachelor | 35 | 10% |
Other | 55 | 16% |
Unknown | 85 | 25% |
Readers by discipline | Count | As % |
---|---|---|
Medicine and Dentistry | 132 | 39% |
Agricultural and Biological Sciences | 30 | 9% |
Biochemistry, Genetics and Molecular Biology | 20 | 6% |
Pharmacology, Toxicology and Pharmaceutical Science | 9 | 3% |
Nursing and Health Professions | 7 | 2% |
Other | 42 | 13% |
Unknown | 96 | 29% |